Immunotherapies, which harness the host immune response to treat cancers have recently generated great excitement in lung cancer treatment, but currently approved therapies, such as immune checkpoint blockades (ICB), are most effective in select patient populations which express high PD-L1 or harbor high tumor mutation burdens and infiltrating immune cells [4, 5]. This evidence concerns the gene CD274 and neoplasm.